OSIP (OSI PHARMACEUTIC)
All Pro Portfolios with OSIP
- Total Pro Portfolios with OSIP:
- Janus Aspen Global Life Sciences Inst JGLIX
- T. Rowe Price Health Sciences Fund - PRHSX
- show more
All Do-It-Yourself Portfolios with OSIP
- Total Do-It-Yourself Portfolios with OSIP:
- steven domenico Portfolio 1
- BIGEDS
- alto28
- 401k pep
- haohao
- DesiGuru - Financial Freedom Investments
- Stock savings account 2005
- robert1903 Portfolio 1
- JOHNABBRUZZESI-STOXX ii
- Edinaite Portfolio 1
- sell
- donk0727 Portfolio 1
- omendrick Portfolio 1
- BENITRANS CK
- fatalwishes Portfolio 1
- ASCO is coming...Papers released May 15
- Top Biotech Short Squeeze Plays
- show more
- 34
- Wall Street 2.0
- Bigroll's pix
- sounds good to me
- LR Portfolio
- PRIMARY1
- raramos76 Portfolio 1
- SUPRATRADE BIOTECH
- Doug_ams
- it's all crazy up in here
- profshan Portfolio 1
- Ryno
- freds market
- scott715
- SUPRATRADE-2309071602
- PART 4 JPMorgan 26th Annual Healthcare Conf 1/8/08..2nd Day Reporting Companies..Nymph Take
- the1duke Portfolio 1
- dpm 1
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
Date:11 19 08 |
|
6.4 |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
OSI Pharma (OSIP) was downgraded from Buy to Neutral, Merrill Lynch said. $46 price target. Valuation call, as data from the Saturn study will likely come out later than expected. |
|
Not yet rated
Rate now:
|
|
By:Tachyon |
Date:10 13 07 |
Tecbnical |
|
Not yet rated
Rate now:
|
|
By:elyodj |
Date:08 24 07 |
BI, checkout this BioTech |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
OSI Pharma upgraded from Underperform to Market Perform, Wachovia said. Company should be able to build upon solid second quarter results, led by Tarceva growth in Europe. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
OSI Pharma (OSIP) was upgraded from Underweight to Overweight, JP Morgan said. Valuation call, as Tarceva should be the major catalyst over the next 12 months. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by CE Unterberg Towbin from Buy to Market Perform |
|
Not yet rated
Rate now:
|
|
By:kisu |
Date:02 27 07 |
This is a cancer and diabetic play. Very likely takeover candidate. Stock has great upside potential |
|
Not yet rated
Rate now:
|
|
By:bbaker58 |
Date:02 11 07 |
PHAR |
|
Not yet rated
Rate now:
|
|
Date:01 23 07 |
|
Out of Favor because of pruchase of EYET (drug Mancugen). Other pipeline strong |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |